Candel Therapeutics Valuation
| CADL Stock | USD 4.84 0.20 3.97% |
At this time, the firm appears to be undervalued. Candel Therapeutics shows a prevailing Real Value of $5.91 per share. The current price of the firm is $4.84. Our model approximates the value of Candel Therapeutics from analyzing the firm fundamentals such as Shares Owned By Insiders of 30.39 %, current valuation of 163.14 M, and Return On Equity of -4.81 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Candel Therapeutics' valuation include:
Price Book 30.408 | Enterprise Value 163.1 M | Enterprise Value Ebitda (0.01) | Price Sales 436.4156 | Forward PE 33.557 |
Undervalued
Today
Please note that Candel Therapeutics' price fluctuation is moderately volatile at this time. Calculation of the real value of Candel Therapeutics is based on 3 months time horizon. Increasing Candel Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Candel stock is determined by what a typical buyer is willing to pay for full or partial control of Candel Therapeutics. Since Candel Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Candel Stock. However, Candel Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.84 | Real 5.91 | Target 9.5 | Hype 4.77 | Naive 4.55 |
The intrinsic value of Candel Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Candel Therapeutics' stock price.
Estimating the potential upside or downside of Candel Therapeutics helps investors to forecast how Candel stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Candel Therapeutics more accurately as focusing exclusively on Candel Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Candel Therapeutics' intrinsic value based on its ongoing forecasts of Candel Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Candel Therapeutics' closest peers.
Candel Therapeutics Cash |
|
Candel Valuation Trend
Knowing Candel Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Candel Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Candel Therapeutics Total Value Analysis
Candel Therapeutics is currently forecasted to have valuation of 163.14 M with market capitalization of 134.29 M, debt of 22.76 M, and cash on hands of 86.78 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Candel Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
163.14 M | 134.29 M | 22.76 M | 86.78 M |
Candel Therapeutics Investor Information
About 30.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.73. Candel Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Candel Therapeutics' liquidity, profitability, solvency, and operating efficiency, Candel Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Candel Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Candel Therapeutics has an asset utilization ratio of 0.0752 percent. This suggests that the Company is making $7.52E-4 for each dollar of assets. An increasing asset utilization means that Candel Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Candel Therapeutics Ownership Allocation
Candel Therapeutics holds a total of 32.48 Million outstanding shares. Candel Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Candel Therapeutics Profitability Analysis
The company reported the previous year's revenue of 31 K. Net Loss for the year was (37.94 M) with loss before overhead, payroll, taxes, and interest of (20.66 M).About Candel Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Candel Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Candel Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Candel Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Candel Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Candel Therapeutics. We calculate exposure to Candel Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Candel Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -24 M | -22.8 M | |
| Pretax Profit Margin | (172.90) | (181.55) | |
| Operating Profit Margin | (319.44) | (335.41) | |
| Net Loss | (20.64) | (21.67) | |
| Gross Profit Margin | (6.21) | (6.52) |
Candel Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Candel Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 28.9 M | |
| Forward Price Earnings | 33.557 |
Candel Therapeutics Current Valuation Indicators
Candel Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Candel Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Candel Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Candel Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Candel Therapeutics' worth.When determining whether Candel Therapeutics is a strong investment it is important to analyze Candel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Candel Therapeutics' future performance. For an informed investment choice regarding Candel Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Revenue Per Share 0.001 | Return On Assets (0.52) | Return On Equity (4.81) |
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.